Q2 2026 saw 44% revenue growth to $335M, led by Oncology and a 257% surge in Screening revenue. Full-year guidance was raised, with Shield adoption accelerating due to new coverage and FDA approvals, and cash reserves remain strong at $1.2B.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.